Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S. patients using generic unbranded versions of the drug.The Danish company last week slashed full-year guidance,

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity drug, with lower growth expected for its treatments in the second half of the year.

The Danish drug maker reiterated its full-year outlook after last week slashing its guidance on weaker second-half U.S. sales growth forecasts for Wegovy and its Ozempic diabetes treatment. The company now expects annual sales growth of 8% to 14% at constant exchange rates, along with annual operating profit growth of 10% to 16%.